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Abstract 
Pompe disease is a rare inherited metabolic and neuromuscular disorder, presenting as a spectrum, with the classic infantile form on one 
end and the more slowly progressive non-classic form on the other end. While being a hallmark in classic infantile Pompe disease, cardiac 
involvement in non-classic Pompe disease seems rare. Vascular abnormalities, such as aneurysms and arterial dolichoectasia, likely caused by 
glycogen accumulation in arterial walls, have been reported in non-classic Pompe patients. With this first systematic review on cardiovascular 
disease in non-classic Pompe disease, we aim to gain insight in the prevalence and etiology of cardiovascular disease in these patients. 
Forty-eight studies (eight case-control studies, 15 cohort studies and 25 case reports/series) were included. Fourteen studies reported cardiac 
findings, 25 studies described vascular findings, and nine studies reported both cardiac and vascular findings. Severe cardiac involvement in 
non-classic Pompe disease patients has rarely been reported, particularly in adult-onset patients carrying the common IVS1 mutation. There 
are indications that intracranial dolichoectasia and aneurysms are more prevalent in non-classic Pompe patients compared to the general 
population. To further investigate the prevalence of cardiovascular disease in non-classic Pompe patients, larger case-control studies that also 
study established cardiovascular risk factors should be conducted. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 



























Pompe disease is an inherited metabolic and 
euromuscular disorder. Mutations in the GAA gene lead 
o deficiency of the enzyme acid α-glucosidase, causing 
ysosomal glycogen accumulation. This ultimately leads to 
ell destruction, mainly causing progressive impairment of 
uscle function [1] . Patients with the classic infantile form 
f Pompe disease have (virtually) no acid a-glucosidase 
ctivity, causing generalized hypotonia, severe hypertrophic 
ardiomyopathy and respiratory failure. Without treatment, 
hese infants die within the first year of life [2] . In non- ∗ Corresponding author. 
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 http://creativecommons.org/licenses/by/4.0/ ) lassic or late onset Pompe disease, residual activity of acid 
-glucosidase causes a more slowly progressive phenotype, 
ith limb-girdle myopathy and respiratory muscle weakness 
s the main symptoms [3] . While severe cardiomyopathy 
s a hallmark of classic infantile Pompe disease, cardiac 
nvolvement in non-classic Pompe disease seems rare [4 , 5] . 
ascular abnormalities such as aneurysms, (vertebrobasilar) 
olichoectasia and arterial dissections have been reported in 
everal cases of non-classic Pompe patients [4 –8] . Pathology 
tudies have shown that glycogen may accumulate in 
ndothelial cells and smooth muscle cells within the media 
f arterial walls of Pompe patients, and it is hypothesized 
hat these changes cause weakness of the arterial wall [9 –13] . 
oreover, we have previously found increased aortic stiffness 
n adults with Pompe disease. This is an independent risk ss article under the CC BY license 
































































































actor for cardiovascular disease and stresses the importance 
f appropriate cardiovascular care in these patients [14 , 15] . 
owever, cardiovascular disease is also very prevalent among 
he general population, and literature on cardiovascular 
isease in non-classic Pompe disease is very diverse, mainly 
onsisting of case reports and relatively small case series 
16] . Therefore at present, it is not clear if patients with 
on-classic Pompe have a higher cardiovascular risk than 
he general aging population and, if this is the case, if this 
s caused by Pompe disease itself or a higher prevalence 
f established cardiovascular risk factors such as physical 
nactivity or obesity. To our knowledge, this is the first 
ystematic review on cardiovascular disease in non-classic 
ompe disease patients. By analyzing the current literature, 
e aim to gain insight in the prevalence and etiology of 
ardiovascular disease in non-classic Pompe disease. This 
otentially could help to formulate diagnostic and monitoring 
trategies, and improve cardiovascular care to prevent serious 
orbidity and even mortality in patients with non-classic 
ompe disease. 
. Methods 
.1. Search strategy 
A systematic search in Embase, Medline Epub (Ovid), 
ochrane Central, Web of Science and Google Scholar was 
erformed on February 14, 2018 and updated in November 
019. Keywords of ‘Pompe disease’ (glycogen storage 
isease type 2, acid maltase deficiency, glycogenosis) and 
ifferent types of ‘cardiovascular disease’ (cardiac disease, 
erebrovascular disease, aneurysm, arrhythmia, stroke) were 
ombined. Studies in animals, conference abstracts and 
ditorials were excluded. The full search strategy is 
ummarized in Appendix 1. 
.2. Selection strategy 
All retrieved publications were reviewed by two 
ndependent reviewers (HvK and CR). There were two stages 
n this process. First, the title and abstract of all retrieved 
ublications were screened by both reviewers. Publications 
rimarily reporting on cardiovascular disease were selected, 
tudies on classic or atypical infantile Pompe disease (these 
atients were not the focus of our study) were excluded. In 
he second stage, full-text articles of the included publications 
ere assessed for eligibility. Studies with no full-text available 
r full-text only in languages other than or English were 
xcluded. Review articles were excluded as well. At both 
tages, discrepancies in selection of publications between 
he two reviewers were discussed, to reach consensus on 
n/exclusion. Remaining uncertainties regarding inclusion 
ere discussed with a third reviewer (PD). The remaining 
ublications included after this stage were reviewed in detail. 
n addition, the reference lists of excluded review articles and 
ll included publications were searched for additional studies 
ot found by our search strategy. 80 .3. Data extraction 
For the included studies, data was extracted using a data 
xtraction table. Extraction was conducted by both reviewers 
nd again compared, to ensure reliability and accuracy of 
he extracted information. Based on the clinic(s) where the 
tudy was conducted, the possibility that different studies 
eported on the same cohort of patients was evaluated. 
e assessed the certainty of the Pompe disease diagnosis 
ased on the techniques mentioned in the article: 1. definite 
ompe disease (genetically confirmed), 2. probable Pompe 
isease (acid α-glucosidase deficiency, combined with muscle 
iopsy abnormalities, or specific Pompe disease symptoms in 
ombination with treatment with ERT) or 3. possible Pompe 
isease (no diagnostics mentioned or only results of a muscle 
iopsy typical for Pompe disease reported). 
.4. Synthesis of results 
Due to heterogeneity of the included studies, a meta- 
nalysis could not be performed. Aiming to overcome the 
ariability and extensiveness of the information retrieved, 
tudy outcomes were grouped into two key themes: 
ardiac findings and vascular findings. Cardiac findings 
ere further grouped into electrocardiogram (ECG) findings 
nd findings on transthoracic echocardiogram (TTE) or 
ther imaging. Findings and events related to vascular 
bnormalities/disease were further divided into six main 
ategories: 1. ectasia/dilatation, 2. aneurysms, 3. stroke, 
. white matter lesions (WML) and microhemorrhages 
MH), 5. pathology findings (PA) and 6. other. Vascular 
ctasias/dilatations and aneurysms were further grouped based 
n their location: anterior cerebral circulation (anterior or 
iddle cerebral artery), vertebrobasilar circulation (vertebral 
r basilar artery), carotid arteries (common or internal carotid 
rtery), aorta, iliac artery, renal artery. 
. Results 
.1. Study selection 
Our literature search retrieved 1482 studies. Through 
eference lists of included studies, three additional studies 
ere included. Forty-one studies fulfilled our criteria and were 
ncluded in the review ( Fig. 1 ). Seven additional studies were 
ncluded from the updated search in November 2019. 
.2. Characteristics of included studies 
The characteristics of the included studies ( n = 48) are 
ummarized in Table 1 . Most studies were case reports 
r case series ( n = 25), eight case control studies and 
5 cohort studies were included. Multiple case-control 
nd cohort studies reported on patients from the same 
ohorts. We considered the diagnosis of Pompe disease 
efinite (genetically confirmed) in 32 studies. Twelve studies 
ere classified as probable Pompe disease (no DNA data 
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Table 1 
Study characteristics. 
Author (year) Patients (N) Pompe diagnosis ∗ Diagnostic modality/modalities Outcome ‡ 
Case-control studies 
Nemes (2007) a [20] 17 1 BP, TTE C, V 
Wens (2014) a [14] 84 1 BP, cervical US, PWV V 
Fayssoil (2014) [19] 10 3 ECG, TTE C 
Hensel (2015) b [34] 10 1 brain MRI/MRA, TCD V 
Morris (2015) [18] 12 3 cardiac MRI, ECG, holter ECG, TTE C 
Boentert (2016) [21] 17 1 CMR C 
Hensel (2018) b [35] 20 1 brain CT/CTA/MRI/MRA V 
Schneider (2019) b [36] 19 1 brain MRI V 
Cohort studies 
Müller-Felber (2007) c [26] 38 1 ECG, holter ECG, TTE C, V 
Soliman (2008) a [22] 46 1 ECG, TTE C 
Van der Beek (2008) a [23] 68 1 ECG, TTE C 
Sacconi (2010) d [37] 6 2 brain MRA V 
El-Gharbawy (2011) [83] 40 1 chest CTA/MRA, CXR, TTE V 
Forsha (2011) a,e [24] 87 1 ECG, TTE C 
Sacconi (2014) [84] 4 1 ECG, holter ECG, TTE C 
Schüller (2012) c [27] 44 1 ECG, TTE C, V 
Montagnese (2016) f [39] 21 1 brain CT/CTA V 
Van Capelle (2016) a [25] 31 1 ECG, TTE C 
Garibaldi (2017) d [38] 5 2 brain MRA V 
Pichiecchio (2017) [63] 18 1 brain CT/CTA/MRI/MRA V 
Herbert (2018) e [29] 83 1 CXR, ECG, TTE C 
Musumeci (2019) f [40] 21 1 brain MRI/MRA, NPP V 
Alandy-Dy (2019) [31] 18 1 NM C, V 
Case reports/case series 
Francesconi (1982) [85] 1 2 ECG, TTE C 
Miyamoto (1985) [86] 2 2 brain CT, PA V 
Braunsdorf (1987) [87] 1 3 brain CT/MRI V 
Makos (1987) [10] 3 2 brain CTA, PA V 
Matsuoka (1988) [88] 1 2 PA V 
Kretzschmar (1990) [9] 1 2 brain CT/MRI, ECG, PA C, V 
Anneser (2005) [89] 1 1 brain CTA/MRI/MRA V 
Brettschneider (2008) [90] 1 1 brain MRI/MRA V 
Laforêt (2008) [91] 3 1 brain CT/CTA/MRI/MRA, cervical US V 
Refai (2008) [55] 1 2 brain CT/MRI, DSA V 
Renard (2010) [92] 1 1 brain MRI/MRA V 
Fernández (2012) [93] 1 1 ECG, TTE C 
Goeber (2013) [94] 1 3 aorta CTA, brain CTA, PA C, V 
Céron-Rodríguez (2014) [95] 1 1 ECG, TTE C 
Peric (2014) [96] 1 1 abdominal US, brain CT/CTA, ECG, TTE V 
Quenardelle (2014) [97] 1 1 brain MRI/MRA, ECG, PA, TTE V 
Sandhu (2014) [98] 1 2 brain CT/MRI/MRA V 
Huded (2016) [99] 2 2 brain CT/MRI, DSA V 
Zhang (2016) [100] 1 1 brain CTA, ECG, TTE C, V 
Kim (2017) [32] 1 1 ECG, TTE C 
Malhotra (2017) [101] 1 2 brain CTA/MRI V 
Mori (2017) [33] 1 2 cardiac MRI, PA, TTE C, V 
Walczak-Galezewska (2017) [102] 1 2 brain MRI, CMR, ECG, TTE C 
Hossain (2018) [103] 1 1 brain CT/MRI, TTE C, V 
Pappa (2018) [104] 1 1 abdominal CT, brain CT/CTA/MRA, renal arteriography V 
∗ 1: definite Pompe disease (genetically confirmed); 2: probable Pompe disease (enzyme activity combined with muscle biopsy abnormalities or enzyme 
activity only or specific Pompe symptoms and treatment with ERT); 3: possible Pompe disease (only muscle biopsy abnormalities or no diagnostics mentioned). 
‡ C: cardiac; V: vascular. a,b,c,d,e,f: studies that (likely) included patients from the same cohort; BP: blood pressure measurement; CMR: cardiovascular 
magnetic resonance; CT: computed tomography; CTA: computed tomography angiography; CXR: chest X-ray; ECG: electrocardiogram; MRA: magnetic 
resonance angiography; MRI: magnetic resonance imaging; NM: not mentioned; NPP: neuropsychological profile; PA: pathology; PWV: pulse wave velocity 
measurement; TCD: transcranial Doppler; TTE: transthoracic echocardiography; US: ultrasound. 
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Fig. 1. Study selection flow diagram (adapted from the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) template [17] ). Seven 






































entioned) and in four studies no specific diagnostics or 
nly muscle biopsy abnormalities were mentioned (based 
n the level of certainty, these studies were classified 
s possible Pompe disease), all patients were included in 
ur review. Most commonly used diagnostic modalities to 
nvestigate cardiovascular disease were: ECG, TTE, magnetic 
esonance imaging (MRI), magnetic resonance angiography 
MRA), computed tomography (CT), computed tomography 
ngiography (CTA) and PA. Fourteen studies reported on 
ardiac outcomes, 25 studies described vascular outcomes, 
nd nine studies reported on both cardiac and vascular 
utcomes. 
.3. Cardiac findings 
The findings of 23 studies reporting on cardiac findings 
re summarized in Table 2 . 
.3.1. Cardiac findings in case-control studies 
In Table 2 A, outcomes of four small case control 
tudies on cardiac outcomes are summarized [18 –21] . Two 
tudies performed ECGs, one of these studies reported no 82 bnormalities in 12 Pompe patients [18] . The other study 
eported one patient with a short PR-interval (sPR) and one 
atient with a right bundle branch block (RBBB), among 10 
ompe disease patients, but ECG findings in controls were not 
eported [19] . In two other studies ECGs were not reported 
20 , 21] . In all four studies echocardiography and/or cardiac 
RI was performed. Two studies, with in total 22 patients 
nd 194 controls, did not find significant differences in 
tructural or functional cardiac features between patients and 
ontrols [18 , 19] . One study reported a larger mean diastolic 
ortic diameter (measured with TTE) in 17 Pompe patients 
ompared to 17 controls [20] . One study reported significant 
ifferences in left ventricular global radial strain (LV-GRS) 
nd left ventricular global circumferential strain (LV-GCS) 
both measures of cardiac deformation), measured with MRI 
etween 17 patients and 18 controls, but findings were within 
he normal range in both groups [21] . 
.3.2. Cardiac findings in cohort studies 
Nine cohort studies reporting on cardiac findings are 
ummarized in Table 2 B. Eight cohort studies (describing 
28 cases in total) performed ECGs. Multiple studies 
H.A. van Kooten, C.H.A. Roelen, E. Brusse et al. Neuromuscular Disorders 31 (2021) 79–90 
Table 2 
Findings of studies focusing on cardiac outcomes. 
A. Case-control studies 
Reference (year) Patients/controls (N) Pompe disease onset (N) Age (years) ∗ Outcomes significantly different 
between patients and controls 
Childhood Adult 
Fayssoil (2014) [19] 10/7 NR NR 56.7 (10.2) –
Morris (2015) [18] 12/187 0 12 37.9 (13.4) –
Boentert (2016) [21] 17/18 4 13 50 (18) HC, LV-GCS, LV-GRS 
B. Cohort studies 
Reference (year) Pts with 
abnormality (N) 
Pompe disease onset (N) Age (years) Findings (N) 
Childhood Adult ECG TTE/imaging CV RF 
Müller-Felber (2007) b 
[26] 
8 6 32 NR VPC (5), WPWs (3) – NR 
Soliman (2008) a [22] 13 0 46 48 (12) ∗ AF (1), LAHB (1), 
LBBB (1), RBBB (1), 
sPR (1) 
BVH (1), DDF (9), dEF 
(1), LVD (1) 
HT (11), DM (2) 
Van der Beek (2008) a 
[23] 
6 23 45 38 (19) ∗ AF (1), LBBB (1), 
LAHB (2), RBBB (1), 
sPR (1), WPWp (1) 
BVH (1), dEF (1), 
LVED (1), VA (1) 
S (2), DM (2), HT 
(1) 
Forsha (2011) a,c [24] 40 NR NR 44 (39–52) ‡ IBBB (2), LAE (3), 
LBBB (1), LVH (10), 
pQRS (1), pQT (3), RAE 
(1), RBBB (1), sPR (8), 
ST (5), WPWs (2) 
dEF (6), LVMI (4) NR 
Schüller (2012) b [27] 19 NR NR 18–62 † RBBB (2), SA (7), SSS 
(1), WPWs (3) 
LVH (6) –
Sacconi (2014) [84] 4 0 131 35- 55 † AVB (4), pQT (1), ST 
(1) 
– –
Van Capelle (2016) a 
[25] 
6 31 0 0.1–17.1 † sPR (3) HCM (2), VA (3) NR 
Herbert (2018) c [29] 29 NR NR 0.5 - 78 † AVB (1), MA (8), 
RBBB (1), SVT (2) 
LAE (4), LVH (14), VD 
(18) 
HT, DM, HL (N?) 
Alandy-dy (2019) [31] 2 5 13 53.7 (14) ∗ NP CM (3) NR 
C. Case reports/case series 
Reference (year) Pompe disease onset (N) Age (years) Findings 
Childhood Adult ECG TTE/imaging PA CV RF 
Francesconi (1982) [85] 1 30 AVB, PES – NR 
Kretzschmar (1990) [9] 1 40 RBBB NP MA NR 
Fernández (2012) [93] 1 12 sPR – NR 
Goeber (2013) [94] 1 48 – LVH, LVD NR 
Céron-Rodríguez (2014) [95] 1 9 VRD BVH, PH, RAE NR 
Zhang (2016) [100] 1 28 – VA NR 
Kim (2017) [32] 1 5 WPWs HCM, LVOT NR 
Mori (2017) [33] 1 33 NP DCM, dEF GS NR 
Walczak-Galezewska (2017) [102] 1 54 – dEF, HMI HC 
Hossain (2018) [103] 1 59 NP LAE, LVH HT 
∗ mean (SD). 
‡ median (interquartile range). 
† range. N : number of patients. a,b,c studies that (likely) included patients from the same cohort; - = no abnormalities; NP: not performed; NR: not reported. 
AF: atrial fibrillation; AVB: atrioventricular block; BVH: biventricular hypertrophy; CM: cardiomyopathy; DCM: dilated cardiomyopathy; DDF: diastolic 
dysfunction; dEF: decreased ejection fraction; DM: diabetes mellitus; ECG: electrocardiogram; GS: lysosomal glycogen storage and myocyte vacuolization; 
HC: hypercholesterolemia; HCM: hypertrophic cardiomyopathy; HL: hyperlipidemia; HMI: heart muscle infiltration; HT: hypertension; IBBB: incomplete bundle 
branch block; LAE: left atrium enlargement; LAHB: left anterior hemi block; LBBB: left bundle branch block; LVD: increased left ventricular diameter; LVED: 
increased left ventricular end-diastolic dimension; LV-GCS: left ventricular global circumferential strain; LV-GRS: left ventricular global radial strain; LVH: 
left ventricular hypertrophy; LVMI: elevated left ventricular mass; LVOT: left ventricular outflow tract obstruction; MA: minor abnormalities (unspecified); 
PA: pathology; PES: pre-excitation syndrome; PH: pulmonary hypertension; pQRS: prolonged QRS-interval; pQT: prolonged QT-interval; RAE: right atrium 
enlargement; RBBB: right bundle branch block; S: smoking; SA: sinusarrhythmia; sPR: short PR-interval; SSS: sick sinus syndrome; ST: sinustachycardia; SVT: 
supraventricular tachycardia; TTE: transthoracic echocardiography; VA: various valve abnormalities; VD: valvular dysfunction; VPC: ventricular premature 
complexes; VRD: ventricular repolarization disorder; WPWp: Wolff-Parkinson-White pattern; WPWs: Wolff–Parkinson–White syndrome. 
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eported on the same cohorts of patients [22 –30] . Sixteen 
ifferent ECG findings were described. Most commonly 
eported findings were sPR, RBBB and Wolf-Parkinson-White 
yndrome (WPWs). The prevalence of these findings varied 
etween different studies: sPR was reported in 1.5–9.7% 
f patients, RBBB in 1.2–6.3% of patients and WPWs in 
.3–7.9% of patients. Signs of left ventricular hypertrophy 
LVH) on ECG were reported in 10/87 (11.5%) of patients 
n one study, only one of these patients showed elevated left 
entricular mass (LVMI) on echocardiography [28] . 
Eight cohort studies performed cardiac imaging 
nd/or function tests using TTE, one study did not 
eport what type of diagnostic modality was used [31] . 
ost commonly reported findings were various valvular 
bnormalities/dysfunction (VA/VD), LVH and decreased 
jection fraction (dEF). The prevalence of these conditions 
n different studies was: 1.5–21.7% for VA/VD, 13.6–16.7% 
or LVH and 1.5–6.9% for dEF. One study reported two 
hildren with a hypertrophic cardiomyopathy (HCM), both 
atients did not carry the common IVS1 mutation and had a 
ery early onset of Pompe disease symptoms (before the age 
f 1) [25] . One study reported three adults (aged 22, 40 and 
2 years) with cardiomyopathy (unspecified) which improved 
ith ERT, of whom one had a childhood onset of Pompe 
isease and did not carry the common IVS1 mutation [31] . 
.3.3. Cardiac findings in case reports and case series 
As summarized in Table 2 C, 10 case reports described 
ardiac findings. Six different ECG findings were described 
n five individual patients (age 5–40 years). One study 
eported WPWs and HCM with left ventricular outflow tract 
bstruction (LVOT) in a five-year-old girl, which improved 
fter start of ERT at age 15 [32] . 
Abnormalities on TTE or other imaging were described in 
even patients, with LVH and dEF being the most common. 
ypertrophic cardiomyopathy was described only in the above 
entioned five-year old girl. One 33-year-old woman with 
 dilated cardiomyopathy (DCM) and myocardial glycogen 
ccumulation (GA) with vacuolization was reported, ERT was 
ot started because of severe and irreversible cardiac muscle 
amage [33] . One other study describing pathology findings 
eported that the heart was “minimally affected”, without 
urther specification of these abnormalities [9] . 
.4. Vascular findings 
In Table 3 , 34 studies reporting on vascular findings are 
ummarized. 
.4.1. Vascular findings in case-control studies 
As shown in Table 3 A, five case control studies focused 
n vascular outcomes. Two studies, reporting on the same 
ohort of patients, reported increased aortic stiffness in 
ompe patients, using aortic stiffness index (ASI) and carotid- 
emoral pulse wave velocity measurement (cfPWV) as non- 
nvasive methods to measure aortic stiffness [14 , 20] . These 
tudies also reported higher mean arterial pressure (MAP) and 84 maller carotid artery diameter in Pompe patients compared 
o controls. 
One study reported a larger diameter of the carotid, 
erebral anterior circulation and vertebrobasilar circulation 
rteries in 10 Pompe patients compared to controls [34] . Also 
arotid and vertebral artery mean flow velocity (MFV) and 
arotid and vertebrobasilar cerebral blood flow (CBF) were 
igher in Pompe patients compared to controls in this study. 
hese 10 patients plus 10 new patients were described in 
nother study, reporting abnormal length, volume and height 
f the bifurcation of the basilar artery in patients compared 
o 40 controls [35] . During five year follow up, one patient 
xperienced an intracerebral hemorrhage (ICH). White matter 
esions were also reported in this study, but the prevalence 
f WML did not differ between patients and controls. This 
ohort of patients was studied again using cerebral MRI, this 
tudy showed no significant difference in Fazekas score and 
ML volume between Pompe patients and controls matched 
or age, sex and number of cerebrovascular risk factors [36] . 
.4.2. Vascular findings in cohort studies 
Eight cohort studies reported on vascular findings, as 
hown in Table 3 B. All studies performed (vascular) imaging 
nd reported on a total of 193 cases. However, the number 
f individual patients is probably lower, since several 
tudies reported on the same cohorts of patients [27 , 30 , 37 –
0] . Most commonly reported findings or events were 
dolicho)ectasias, aneurysms, strokes and WML. Six studies 
eported (dolicho)ectasias of the vertebrobasilar circulation 
VBD), the carotid arteries (CAE) and the anterior circulation 
ACD). The prevalence of these findings varied between 
ifferent studies: VBD was reported in 2–72% of patients, 
AE in 39–50% of patients and ACD in 28% of patients. 
ne study reported no significant changes in MRA findings 
nd no major vascular events during 10-year follow up 
f five patients with VBD and CAE [38] . Four studies 
eported aneurysms; anterior circulation aneurysms (ACA) 
ere reported in 2–14% of patients, aortic aneurysms (AA) 
ere reported in 2–10% of patients and vertebrobasilar 
neurysms (VBA) were reported in 3–6% of patients. Strokes 
ere reported in five studies, with ischemic stroke (IS) 
ccurring in 3–10% of patients. White mater lesions were 
ommonly reported, with a prevalence ranging from 62% to 
00% of patients. 
.4.3. Vascular findings in case reports and case series 
In Table 3 C, 20 case reports/series reporting on vascular 
ndings are summarized. Vascular abnormalities or events in 
5 individual patients were reported. In total, 19 cases of 
dolicho)ectasia at various locations (vertebrobasilar ( n = 8), 
iffuse cerebral ( n = 5), carotid arteries ( n = 3), anterior 
irculation ( n = 1), renal artery ( n = 1) and iliac artery ( n = 1))
ere reported. Ages of the reported patients ranged from 16 
o 68 years. Ten aneurysms (located at the vertebrobasilar 
irculation ( n = 7), anterior circulation ( n = 2) and aorta 
 n = 1)) were described in patients aged 16–59 years. In 
ve patients rupture of an intracerebral aneurysm caused 
H.A. van Kooten, C.H.A. Roelen, E. Brusse et al. Neuromuscular Disorders 31 (2021) 79–90 
Table 3 
Findings of studies focusing on vascular outcomes. 
A. Case-control studies 
Reference (year) Patients/ controls (N) Pompe disease onset (N) Age (years) Outcomes significantly different between 
patients and controls Childhood Adult 
Nemes (2007) a [20] 17/17 17 44 (8) ∗ ASI, BMI, DAD 
Wens (2014) a [14] 84/179 NR NR 54 (42-63) ‡ ART, CA-D, cfPWV, HR, HT, MAP 
Hensel (2015) b [34] 10/20 1 9 44-71 † BA-CBF, BA-D, CA-CBF, CA-D, 
CA-MFV, MCA-D, VA-CBF, VA-D, 
VA-MFV 
Hensel (2018) b [35] 20/40 3 17 53.7 (14.6) ∗ BA-D, BA-H, BA-L, BA-V, SUCA-OA 
Schneider (2019) b [36] 19/38 3 17 54.4 (19-82) × - 
B. Cohort studies 
Reference (year) Pts with abnormality 
(N) 
Pompe disease onset (N) Age (years) Findings/events related to vascular abnormalities (N) 
Childhood Adult Ectasia/ 
dilatation 
Aneurysm Stroke WML/MH CV RF Other 
Müller-Felber (2007) c 
[26] 
1 1 28 IS NR 
Sacconi (2010) [37] 4 4 38-69 † CAE (3), 
VBD (4) 
TIA (1) - 
El-Gharbawy (2011) 
[83] 
5 1 4 33-64 † AA (4), VBA 
(1) 
HT (1), HL (1), HC 
(1) 
AD (1) 
Schüller (2012) c [27] 3 NR NR 30-53 † VBD (1) AA (1), ACA 
(1) 
IS (2) - 
Montagnese (2016) 
[39] 
18 1 17 50 (14.97) ∗ VBD (10) ACA (2) IS (2) WML (13) HT (5), S (4), OB (3), 
HC (4) 
BA-F (1) 





1 2 13 52.3 (28-76) × ACD (5), 
CAE (7), 
VBD (13) 
WML (6) S (5), OB (2), DM 
(2), HC (4), HT (4) 
PSG (4) 
Musumeci (2019) e 
[40] 
21 4 17 49 (1.4) ∗ VBD (11) ACA (3) WML (21) S (7), HT (7), HC (5) 
Alandy-Dy (2019) [31] 1 5 13 53.7 (14) ∗ VBA (1) NR 
C. Case reports/case series 
Reference (year) Pompe disease onset (N) Age (years) Findings/events related to vascular abnormalities (N) 
Childhood Adult Ectasia/ 
dilatation 
Aneurysm Stroke WML/MH PA CV RF Other 
Miyamoto (1985) [86] 1 25 VBA SAH VAC NR 
Braunsdorf (1987) [87] NR NR 34 CAE VBA WML NR 
Makos (1987) [10] 2 1 16-27 † CAE (1), VBD 
(2) 
VBA (2) IS (1), SAH (2) GA, VAC NR 
Matsuoka (1988) [88] 1 20 VBA IS, SAH VAC NR 
Kretzschmar (1990) [9] 1 40 MH GA, VAC NR 
Anneser (2005) [89] 1 30 DCD MH - 
Brettscheider (2008) [90] 1 68 ICH MH - 
Laforêt (2008) [91] 2 1 30-44 † DCD (1), VBD 
(1) 
VBA (1) NR DCP (1), 
ICD (1) 
Refai (2008) [55] 1 19 VBD IS NR 
Renard (2010) [92] 1 68 ACD, VBD MH - 
Goeber (2013) [94] 1 48 VBD AA GA NR ENV 
Peric (2014) [96] 1 50 ACA SAH - 
Quenardelle (2014) [97] 1 52 CAE, IAD, RAD, 
VBD 
IS - - KI 
Sandhu (2014) [98] NR NR 25 DCD ICH MH HT 
Huded (2016) [99] 2 40, 43 DCD (2) IS (2) MH (1) NR 
Zhang (2016) [100] 1 28 VBA NR 
Malhotra (2017) [101] 1 40 VBD IS NR BA-S 
Mori (2017) [33] 1 33 IS NR 
Hossain (2018) [103] 1 57 ACA IS, SAH WML HT 
Pappa (2018) [104] 1 38 ICH - KI, RAD 
N: number of patients a,b,c , studies that (likely) included patients from the same cohort, d follow up of 5/6 patients of Sacconi (2010), e findings of 17/21 
patients were previously reported by Montagnese (2016); ∗ mean (SD); ‡ median (interquartile range); ×median (range); † range; NR: not reported; - no 
abnormalities; AA: aortic aneurysm; ACA: anterior circulation aneurysm; ACD: anterior circulation (dolicho)ectasia/dilatation; AD: aortic dissection; ART: 
aortic reflexion time; ASI: aortic stiffness index; BA-CBF: basilar artery cerebral blood flow; BA-D: basilar artery diameter; BA-F: basilar artery fenestration; 
BA-H: height of basilar artery bifurcation; BA-L: basilar artery length; BA-S: basilar artery stenosis; BA-V: basilar artery volume; BMI: body mass index; 
DM: diabetes mellitus; CA-CBF: carotid artery cerebral blood flow; CA-D: carotid artery diameter; CAE: carotid artery ectasia/dilatation; CA-MFV: carotid 
artery mean flow velocity; cfPWV: carotid-femoral pulse wave velocity; CV RF: cardiovascular risk factors; DAD: diastolic aortic diameter; DCD: diffuse 
cerebral (dolicho)ectasia/dilatation; DCP: diffuse cerebral pseudo-aneurysm; ENV: elongated neck vessels; GA: glycogen accumulation in vascular smooth 
muscle cells; HC: hypercholesterolemia; HT: hypertension; HR: heart rate; IAD: iliac artery dilatation; ICD: internal carotid artery dissection; ICH: intracranial 
hemorrhage; IS: ischemic stroke; KI: kidney infarct; MAP: mean arterial pressure; MCA-D: mid cerebral artery diameter; MH: microhemorrhages; OB: obesity; 
PA: pathology; PSG: punctate subcortical gliosis; RAD: renal artery dilatation; SAH: subarachnoid hemorrhage; SUCA-OA: superior cerebellar artery outlet 
angle; TIA: transient ischemic attack; VAC: vacuolar changes in vascular smooth muscle cells; VA-CBF: vertebral artery cerebral blood flow; VA-D: vertebral 
artery diameter; VA-MFV: vertebral artery mean flow velocity; VBA: vertebrobasilar circulation aneurysm; VBD: vertebrobasilar (dolicho)ectasia/dilatation; 
WML: white matter lesions. 
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 subarachnoid hemorrhage (SAH). Ischemic strokes were 
eported in nine patients (aged 19–59 years), ICH in three 
atients (aged 25–68 years). Six patients with MH and two 
atients with WML were reported. Pathology findings were 
escribed in six studies; five of these studies reported vacuolar 
hanges and/or glycogen accumulation within smooth muscle 
ells in the media of the arterial walls, one study reported no 
bnormalities. Two patients with a kidney infarct (KI) and one 
atient with a dissection of the internal carotid artery (ICD) 
ere reported. 
.5. Cardiovascular risk factors 
Reported cardiovascular risk factors for all studies are 
ummarized in Tables 2 and 3 . For case control studies, only 
isk factors between patients and controls being significantly 
ifferent are reported in the tables. Non-significantly different 
ardiovascular risk factors reported in these case-control 
tudies were: hypertension (30–70%), hypercholesterolemia/ 
yperlipidemia (10–70%), diabetes mellitus (6–20%), obesity 
18–40%), and smoking (5–30%). In the cohort studies, 
ypertension was reported in 22–33%, diabetes in 4–11%, 
moking in 19–33%, hypercholesterolemia/hyperlipidemia in 
9–24% and obesity in 11–14% of patients. 
. Discussion 
To our knowledge, this is the first systematic review on 
ardiovascular disease in non-classic Pompe disease. It gives 
 comprehensive overview of the present literature. A large 
umber of studies were included ( n = 48), reporting on 750 
ases in total. However, the exact number of individual 
atients is difficult to estimate, since several studies reported 
n the same cohorts of patients. Moreover, we could not 
etermine the level of diagnostic certainty of all patients 
n the included papers, as in some cases or papers the 
iagnosis was not genetically confirmed, or the DNA results 
ere not reported. Also, the level of evidence of the studies 
as variable, a large proportion of the included studies 
re case reports or case series ( n = 25) and outcomes and 
sed methodologies vary greatly. It was not possible to 
erform meta-analysis, but a thorough qualitative analysis was 
erformed. 
In case-control studies, no significant differences between 
atients and controls were reported for ECG findings [18 , 19] . 
owever, patient numbers were small. In cohort studies, 
arious ECG/conduction abnormalities were described, with 
PR, RBBB and WPW pattern/syndrome being the most 
ommon. The cause of conduction abnormalities in non- 
lassic Pompe patients may be glycogen accumulation in 
he myocardium and/or conduction system [ 11 , 41] . However, 
inor ECG findings and conduction abnormalities, like 
BBB, have a high prevalence in the general, healthy 
opulation as well [42] . Wolff–Parkinson–White syndrome 
r pattern was reported in 2.3–7.9% of patients in different 
ohorts, whereas the prevalence of WPW pattern in 
he general population is estimated to be around 0.25% 86  42 –47] . Since different types of (severe) arrhythmias and 
ven sudden cardiac death can occur in patients with WPW 
attern, it seems important that an ECG is conducted at 
east once in all newly diagnosed non-classic Pompe disease 
atients [48 , 49] . In patients with a normal ECG at baseline, 
epeated ECG could be considered, since WPW pattern 
ay be intermittent and Pompe disease is, despite ERT, a 
rogressive disaese [50 , 51] . It can therefore not be ruled 
ut that glycogen accumulation in cardiac tissue causes 
onduction abnormalities as the disease progresses. 
In case-control studies, severe structural cardiac 
bnormalities or cardiac dysfunction on TTE or other 
maging were not described. In cohort studies, LVH was 
he most commonly reported TTE/imaging abnormality. Left 
entricular hypertrophy or elevated LVMI, was described in 
.6–16.7% of patients, which is comparable to the prevalence 
n the general population [24 , 27 , 29 , 52] . Left ventricular 
ypertrophy is mainly caused by long-term pressure and/or 
olume overload, consequently the prevalence of LVH is 
igher in a population with high blood pressure [53] . One 
tudy reported that all patients with LVH also had other 
ardiovascular risk factors, including hypertension [29] . The 
ther studies did not report whether patients with LVH also 
ad hypertension, but since mean blood pressure is reported 
o be increased in non-classic Pompe patients, it is likely 
hat hypertension was prevalent in these cohorts as well 
14] . Hypertrophic cardiomyopathy, a hallmark in classic 
nfantile Pompe disease, was described in only three patients 
n the retrieved studies [25 , 32] . However, these patients 
id not carry the common IVS1 mutation and had a (very) 
arly onset of disease, and therefore might be classified 
s atypical infantile onset patients, rather than non-classic 
ompe patients. Only one adult patient, with one mutation 
ith unknown pathogenicity, was reported to have severe 
ilated cardiomyopathy [33] . 
The most commonly reported vascular abnormalities in 
on-classic Pompe patients were (dolicho)ectasias, with a 
redisposition for the vertebral and/or basilar arteries. One 
ase-control study showed an increased diameter of extra- 
nd intracranial arteries in patients compared to controls 
atched for age and sex [34] . Importantly, the presence 
f other cardiovascular risk factors was distributed evenly 
mong patients and controls in this study. In cohort 
tudies, the prevalence of VBD varied between 2% and 
2%. Reported estimates of prevalence of VBD in the 
eneral population vary from 0.8% to 6.5%, indicating 
hat VBD is more prevalent in Pompe patients [54] . 
oreover, (dolicho)ectasias were also described in (very) 
oung Pompe disease patients, with the youngest patient 
eing only 19 years old [55] . Other important vascular 
bnormalities commonly reported in the included studies 
ere intracranial (anterior and vertebrobasilar circulation) and 
ortic aneurysms. Intracranial aneurysms were reported in 
p to 14% of Pompe patients in different cohort studies, 
hereas the prevalence of intracranial aneurysms is estimated 
o be 3.2% in a population without comorbidity [56] . The 
athophysiology of these vascular abnormalities is most 















































































































ikely multifactorial, as both degeneration of smooth muscle 
ells of arterial walls caused by glycogen accumulation 
nd established cardiovascular risk factors (i.e. hypertension, 
igarette smoking, aging) are associated with (dolicho)ectasia 
nd aneurysm formation [54 , 57-59] . Although asymptomatic 
n a proportion of patients, the consequences of intracranial 
dolicho)ectasia and aneurysms can be serious, with brain 
nfarction, ICH and SAH, and compression of the brainstem 
eing most common [54 , 60] . Interestingly, ICH and/or SAH 
s a consequence of intracranial dolichoectasia or aneurysms 
ere only reported in case reports/series and not in any of 
he cohort studies. Previous studies have shown that ERT can 
ecrease glycogen in arteries and veins, but not completely 
nd not in all patients [ 6 , 61 , 62] . However, as established
ascular risk factors also contribute to the pathophysiological 
echanisms of arterial widening, monitoring and treatment 
f these risk factors is particularly important in patients with 
on-classic Pompe disease. 
White matter lesions in a lacunar pattern, characteristic 
or small vessel disease, were reported in a large proportion 
f patients in different cohort studies [39 , 40 , 63] . However, 
ost of these patients also had other (established) vascular 
isk factors. Moreover, in a case-control study, Fazekas score 
nd WML volume did not significantly differ between Pompe 
atients and controls matched for gender, age and number of 
erebrovascular risk factors [36] . This suggests that WML 
n Pompe patients mainly result from other (established) 
erebrovascular risk factors. The lacunar pattern of WML 
eported in non-classic Pompe patients is clearly distinct from 
he white-matter involvement, which slowly evolves from 
eriventricular to subcortical, described in classic infantile 
ompe disease [64] . Severe cognitive decline, as reported 
n some classic infantile Pompe disease patients, was not 
eported in non-classic Pompe patients, although one study 
eported mild cognitive impairment in 52% of patients 
40 , 64 , 65] . The severity of WML did not correlate with
europsychological variables in this study, indicating that 
ther factors may play a role in the cognitive impairment 
n these patients. 
As stated previously, arterial stiffness, LVH and WML in 
ompe disease patients may also be caused by established 
ardiovascular risk factors, such as obesity, hypertension, 
iabetes mellitus and dyslipidemia [53 , 66 –68] . No large study 
ystematically investigated if established cardiovascular risk 
actors are more prevalent in Pompe disease than in the 
eneral population. Studies in Pompe patients reported a 
arge prevalence range for various cardiovascular risk factors, 
uch as for hypertension (22–70%), diabetes (4–20%), and 
besity (11–40%). Whether this is different compared to the 
revalence of these risk factors in the general population 
emains to be established. The prevalence of hypertension in 
dults is estimated to be around 30–45% and increases to over 
0% in individuals over the age of 60 years [69] . The global 
revalence of diabetes in the general population is estimated 
o be around 9%, with great variation due to age, regional, 
ncome and ethnic differences [70] . Global prevalence of 
besity is estimated to be around 13%, increasing up to 87 6% in high income countries [71] . These large ranges 
mply that larger case-control studies in Pompe patients are 
eeded before reliable conclusions about these risk factors 
n comparison to the general population can be drawn. As 
ompe disease affects skeletal muscle function, resulting 
n decreased overall activity level and ability to exercise 
nd decreased resting energy, we hypothesize that these 
ardiovascular risk factors may be more prevalent in non- 
lassic Pompe patients compared to the general population. 
his should be objectified in future studies. 
It is important to realize that there are large differences 
etween muscle glycogen storage diseases (GSD) in 
espect to the presence of cardiac abnormalities. In 
uscle glycogen synthase deficiency (GSD 0b) hypertrophic 
ardiomyopathy is a key clinical finding [72 , 73] . In muscle 
hosphofructokinase (PFKM) deficiency or Tarui disease 
GSD VII) cardiomyopathy is rare, but has been described 
74] . In phosphoglucomutase 1 deficiency in muscle (GSD 
IV) dilated cardiomyopathy and tachycardia have been 
escribed in some patients [ 75 –77] . Arrhythmias and 
ardiomyopathy due to abnormal glycogen storage in the heart 
re characteristic for glycogenin 1 deficiency (GSD XV) [ 77 –
9] . Mutations in the PRKAG2 gene cause glycogen storage 
ardiomyopathy and conduction system abnormalities [80] . 
owever, not all muscle glycogenoses are associated with 
ardiac involvement (e.g. muscle phosphorylase deficiency 
r McArdle disease (GSD V), phosphoglycerate kinase 
eficiency, lactate dehydrogenase A and B deficiency (GSD 
I), aldolase A deficiency (GSD XII), beta-enolase deficiency 
n muscle (GSD XIII)) [81 , 82] . Interestingly, arterial ectasia, 
ilation and aneurysms as reported in Pompe disease, are not 
haracteristic for other muscle glycogenoses [81] . 
This is the first systemic review that provides an overview 
f different types of cardiovascular disease described in 
on-classic Pompe disease. Besides some indications that 
intracranial) arterial dolichoectasia and aneurysms may 
e more common in Pompe disease than in the general 
opulation, we found no literature evidence for other 
linically significant cardiovascular abnormalities in non- 
lassic Pompe disease patients, in particular in those 
atients carrying the common IVS1 mutation. Different 
ypes of ECG/conduction abnormalities were reported in 
ohort studies, but a relationship with Pompe disease 
emains uncertain, and argues for additional (larger) case- 
ontrol studies. Currently, it seems recommendable to 
erform an ECG at least once in every newly diagnosed 
ompe patient, to investigate for possible arrhythmias 
r conduction abnormalities. To further investigate the 
revalence of cardiovascular disease in non-classic Pompe 
atients, especially larger case-control studies, that also 
nvestigate more established risk factors for cardiovascular 
isease are indicated. Ideally, patients and controls should be 
atched not only for age and sex, but also for a variety of 
stablished cardiovascular risk factors, in order to draw more 
obust conclusions about the prevalence of cardiovascular 
isease in non-classic Pompe disease. Due to the prevalence 
f the disease, this may require international collaboration. 
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